Association of infliximab and vedolizumab trough levels with reported rates of adverse events: A cross-sectional study

Ido Veisman, Oranit Barzilay, Liora Bruckmayer, Ola Haj-Natour, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin, Bella Ungar*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Association of infliximab and vedolizumab trough levels with reported rates of adverse events: A cross-sectional study'. Together they form a unique fingerprint.

Medicine & Life Sciences